Drug Profile
Research programme: CAR-T cell based therapeutics - Autolus
Alternative Names: Dominant negative SHP2 protein engineered CAR T-cells - Autolus; Engineered T-cell immunotherapeutics- AutolusLatest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator University College London
- Developer Autolus
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for preclinical development in Multiple-myeloma in United Kingdom (Parenteral, Infusion)
- 22 Mar 2017 Pharmacodynamics data from preclinical trial in Multiple myeloma presented at the American Society of Hematology 58th Annual Meeting (ASH-Hem-2016)
- 21 Mar 2017 CAR-T cell based therapeutics - Autolus is available for licensing as of 21 Mar 2017. http://www.autolus.com/about-us/overview